Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Ruxolitinib Cream Clear all

Conditions: NonSegmental Vitiligo
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 79
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 66 more

Conditions: Alopecia Areata
Interventions: Placebo Cream, Ruxolitinib Phosphate Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • New Haven, Connecticut + 15 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 476 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Acute Skin Graft Versus Host Disease (GVHD)
Interventions: Ruxolitinib 1.5% cream; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 2 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Seborrheic Dermatitis
Interventions: Ruxolitinib 1.5% Cream; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Graft Versus Host Disease, JNS Kinase, Topical Administration
Interventions: Ruxolitinib 1.5% cream, vehicle cream; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1.5% Cream BID, Triamcinolone 0.1% Cream BID, Vehicle Cream BID; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Birmingham, Alabama • Bryant, Arkansas • Encino, California + 28 more

Conditions: Vitiligo
Interventions: ruxolitinib, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 44
States / cities: Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more

Conditions: Atopic Dermatitis
Interventions: ruxolitinib cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 30
States / cities: Fountain Valley, California • Long Beach, California • Washington D.C., District of Columbia + 26 more

Conditions: Discoid Lupus Erythematosus
Interventions: Ruxolitinib; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hidradenitis Suppurativa
Interventions: Ruxolitinib Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Phoenix, Arizona • Fountain Valley, California • Northridge, California + 17 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Culver City, California

Conditions: Vitiligo
Interventions: Ruxolitinib 1.5% Phosphate Cream; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Hand Eczema (CHE)
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • Huntington Beach, California • Westminster, California + 8 more

Conditions: Necrobiosis Lipoidica
Interventions: Ruxolitinib; Drug
Lead sponsor: Aaron R. Mangold; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Prurigo
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 15 more

Conditions: Psoriasis
Interventions: Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more

Conditions: Healthy Participants
Interventions: Povorcitinib, Ruxolitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more

Conditions: Hidradenitis Suppurativa
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 67
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 57 more

Conditions: Vitiligo
Interventions: Ruxolitinib 1.5% cream, NB-UVB phototherapy; Drug · Device
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: Fountain Valley, California • Sacramento, California • Sunnyvale, California + 8 more

Conditions: Pyoderma Gangrenosum
Interventions: topical ruxolitinib 1.5% cream; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atopic Dermatitis (AD)
Interventions: CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD; Drug
Lead sponsor: CAGE Bio Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Fremont, California

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Anaheim, California + 12 more

Search by objective public record fields.

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)

Ruxolitinib in Seborrheic Dermatitis

Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

Topical Ruxolitinib for the Treatment of Vitiligo

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

Study of Ruxolitinib Cream in Children With Atopic Dermatitis